Bedwetting
Nocturia
EAU Edu Platform for the male lower urinary tract symptoms
Home
Articles
Videos
Webcasts
Education
E-courses
Webinar
Guidelines
Events
Home
Articles
Videos
Webcasts
Education
Terug
E-courses
Webinar
Guidelines
Events
Upcoming event
7th Meeting of the EAU Section of Uro-Technology in conjunction with the German Working Groups of Endourology, Laparoscopy and Robotic Assisted Surgery (ESUT20) (ESUT20)
Home
/
Guidelines
Back
Tags
5α-Reductase inhibitors
,
Aquablation
,
Avanafil
,
Benign Prostatic Diseases
,
Bladder injury
,
Bladder outlet obstruction
,
Bladder trauma
,
BOO
,
BOOI
,
BPD
,
BPE
,
BPH
,
BPO
,
Chronic bacterial prostatitis
,
CP/CPPS
,
CPPS
,
Desmopressin
,
Detrusor
,
Detrusor hypocontractility
,
Dihydrotestosterone
,
Drug adherence
,
Drug therapy
,
Dutasteride
,
EAU
,
Ejaculation
,
Ejaculation preservation
,
Ejaculatory dysfunction
,
Endoscopic surgery
,
Epidemiology
,
Erectile dysfunction
,
Fexapotide triflutate
,
Fibrosis
,
Finasteride
,
Frequency volume chart
,
GL-XPS
,
Guidelines
,
Herbal medicines
,
Hypogonadism
,
Impaired contractility
,
Incontinence
,
Infertility
,
Inflammation
,
Inflammatory biomarkers
,
Innervation
,
IPP
,
IPSS
,
iTIND
,
Laparoscopy
,
Laser Bipolar
,
Laser prostatectomy
,
Laser therapy
,
LUT
,
LUTS
,
Major cardiac adverse event
,
Management of Non-Neurogenic LUTS incl. BPO
,
Medical therapy
,
Meta analysis
,
Meta regression
,
Metabolic syndrome
,
Microbiome
,
Micturition chart
,
Minimally invasive surgical therapy
,
minimally invasive techniques
,
Mirabegron
,
Monotherapies
,
Muscarinic antagonist
,
nitinol
,
Nocturia
,
Noninvasive
,
NX-1207
,
Overactive bladder
,
Pathogenesis
,
Pathophysiology
,
Patient satisfaction
,
Patient-reported outcome
,
Permixon
,
Pharmacology
,
Phenotypically directed multimodal management
,
Phosphodiesterase type 5 inhibitor
,
Phosphodiesterase type 5 inhibitors
,
Phytotherapy
,
Placebo effect
,
Prospective study
,
Prostate
,
Prostate surgery
,
Prostate-specific antigen
,
Prostatectomy
,
Prostatic
,
Prostatic artery embolization
,
Prostatic hyperplasia
,
Prostatitis
,
PUL
,
Quality of life
,
Randomized trial
,
RASP
,
Remission
,
Retrograde ejaculation
,
Robotic
,
Robotic surgery
,
Robotics
,
Serenoa repens
,
Sexual Dysfunction
,
Sexual dysfunctions
,
Sildenafil
,
Simple prostatectomy
,
Solifenacin
,
Stem cells
,
Surgery
,
Surgical intervention
,
Systematic review
,
Tadalafil
,
Tamsulosin
,
Telomerase
,
Testosterone
,
TUR syndrome
,
TURis
,
TURP
,
Ultrasonography
,
Underactive bladder
,
urethral implantable device
,
Urethral injury
,
Urethral trauma
,
Urinary Incontinence in Adults
,
Urinary nerve growth factor
,
Urinary sphincter
,
Urodynamics
,
Urolift
,
Vardenafil
,
Voiding
,
Voiding dysfunction
,
α-Adrenergic blocker
,
α-Adrenoceptor antagonists
,
α-Blocker
,
α-blockers
,
α1-Blockers
Show all
Urinary Incontinence
European Association of Urology
View
Treatment of Non-neurogenic Male LUTS
European Association of Urology
View
2010 Update: Guidelines for the management of benign prostatic hyperplasia
Can Urol Assoc J. , Volume 4, Issue 5, October 2010, Pages 310-316
View
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
I agree
Read more